TELA Bio TELA 深 沪
等待开盘 04-02 09:30:00 美东时间
0.5688
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.5688
- 总市值 2544.83万
- 52周最高 2.20
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.544
- 委 比 0.00%
- 总股本 4474.04万
- 历史最高 23.545
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.544
- 每 手 1
- 风险率 0.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
美股大行评级 | 最高240美元，潜在涨幅53%！ARM获多家大行上调目标价；Braze 评级上演 “两极反转”，小摩、巴克莱上调，高盛、花旗下调
今日重点评级关注：HC Wainwright & Co.：维持OCUGEN"买入"评级，目标价从7美元升至10美元；HC Wainwright & Co.：维持Maze Therapeutics"买入"评级，目标价从60美元升至110美元
03-26 11:41
TELA Bio Analysts Cut Their Forecasts After Q4 Results
TELA Bio (NASDAQ:TELA) reported mixed Q4 results, with higher losses but lower sales than expected. Analysts lowered price targets for the stock.
03-26 04:37
Amazon To Rally Around 49%? Here Are 10 Top Analyst Forecasts For Wednesday
Top analysts change outlook for top names. Citigroup, Tigress Fin, Piper Sandler, Morgan Stanley, HC Wainwright, Susquehanna, Raymond James and Goldman Sachs adjust price targets for companies like Braze, Amazon, TELA Bio, Smithfield Foods, Corcept Therapeutics, TechnipFMC, Phillips 66, and KB Home. See all changes at benzinga.com/analyst-stock-ratings.
03-26 04:11
Canaccord Genuity Maintains Buy on TELA Bio, Lowers Price Target to $2
Canaccord Genuity analyst Caitlin Roberts maintains TELA Bio (NASDAQ:TELA) with a Buy and lowers the price target from $4 to $2.
03-25 22:00
电话会总结 ｜ TELA Bio(TELA)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据TELA Bio业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 2025年第四季度营收2,090万美元，同比增长18% - 2025年全年营收8,030万美元，同比增长16% - OviTex产品全年增长12%，OviTex PRS产品全年增长20% - LiquiFix产品营收较上年增长超过两倍 - 欧洲销售占总营收15%，达1,210万美元，同比增长17% **盈利能力：** - 第四季度毛利率66%，全年毛利率68%，较上年同期的64%和67%有所改善 - 运营亏损：第四季度660万美元，全年3,380万
03-25 12:04
TELA Bio FY2026 Revenue expected to be more than $86.697M vs $92.674M Est
TELA Bio (NASDAQ:TELA) FY2026 Revenue expected to be more than $86.697M vs $92.674M Est
03-25 04:17
TELA Bio Q4 EPS $(0.17) Beats $(0.18) Estimate, Sales $20.869M Miss $21.047M Estimate
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 26.09 percent increase over losses of $(0.23) per share from the same
03-25 04:15
Earnings Scheduled For March 24, 2026
Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...
03-24 19:11
TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results
NotificationCenter TELA Bio, Inc. announced it will report its fourth quarter and full year 2025 financial results on March 24, 2026. The company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
03-10 20:05
